Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Bluebells hold hope for HIV remedy

Wednesday 11 September 1996 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Bluebells and daffodils contain proteins which could form the basis of new drugs for combating HIV, the virus which can cause Aids, researchers announced at the British Association, writes Nicholas Schoon.

The hope is that these proteins, known as lectins, can be developed into compounds which block a crucial phase in the lifecycle of the virus - the point when it recognises and attaches itself to human immune cells. This attachment is the prelude to the attack which eventually wipes out the immune system and causes full-blown Aids, leaving victims prey to infection.

A team from Liverpool John Moores University and the nearby Daresbury Laboratory in Cheshire has been using X-ray to discover thestructure of various lectins, in the hope that they can learn how they block the HIV virus and why some lectins are more effective than others.

"The results so far are a breakthrough but we still have a lot of work to do," said Pierre Rizkallah of the Daresbury Laboratory, owned and run by research councils. He estimated it would take at least another five years before the scientists would know whether a lectin-based drug was a possibility.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in